Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin

Many chemotherapy regiments are successfully used to treat breast cancer; however, often breast cancer cells develop drug resistance that usually leads to a relapse and worsening of prognosis. We have shown recently that epigenetic changes such as DNA methylation and histone modifications play an important role in breast cancer cell resistance to chemotherapeutic agents. Another mechanism of gene expression control is mediated via the function of small regulatory RNA, particularly microRNA (miRNA); its role in cancer cell drug resistance still remains unexplored. In the present study, we investigated the role of miRNA in the resistance of human MCF-7 breast adenocarcinoma cells to doxorubicin (DOX). Here, we for the first time show that DOX-resistant MCF-7 cells (MCF-7/DOX) exhibit a considerable dysregulation of the miRNAome profile and altered expression of miRNA processing enzymes Dicer and Argonaute 2. The mechanistic link of miRNAome deregulation and the multidrug-resistant phenotype of MCF-7/DOX cells was evidenced by a remarkable correlation between specific miRNA expression and corresponding changes in protein levels of their targets, specifically those ones that have a documented role in cancer drug resistance. Furthermore, we show that microRNA-451 regulates the expression of multidrug resistance 1 gene. More importantly, transfection of the MCF-7/DOX-resistant cells with microRNA-451 resulted in the increased sensitivity of cells to DOX, indicating that correction of altered expression of miRNA may have significant implications for therapeutic strategies aiming to overcome cancer cell resistance. [Mol Cancer Ther 2008;7(7):2152–9]

[1]  M. Lehnert.  Chemotherapy resistance in breast cancer. , 1998, Anticancer research.

[2]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[4]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[5]  C. Boland,et al.  BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells , 2003, British Journal of Cancer.

[6]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[7]  A. El-Osta,et al.  MDR1, Chemotherapy and chromatin remodeling , 2004, Cancer biology & therapy.

[8]  A. Marzo,et al.  MDR1 Promoter Hypermethylation in MCF-7 Human Breast Cancer Cells: Changes in Chromatin Structure Induced by Treatment with 5-Aza-Cytidine , 2004, Cancer biology & therapy.

[9]  F. Slack,et al.  RAS Is Regulated by the let-7 MicroRNA Family , 2005, Cell.

[10]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[11]  Yoko Fukuda,et al.  Exploration of human miRNA target genes in neuronal differentiation. , 2005, Nucleic acids symposium series.

[12]  George A. Calin,et al.  Mammalian microRNAs: a small world for fine-tuning gene expression , 2006, Mammalian Genome.

[13]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[14]  T. Sakaeda,et al.  An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. , 2006, Current pharmaceutical design.

[15]  Dario La Sala,et al.  Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug‐resistant tumors: Current views and new therapeutic prospective , 2006, Journal of cellular physiology.

[16]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[17]  H. Lage.  MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. , 2006, Current drug targets.

[18]  S. Swain,et al.  Emerging drugs to replace current leaders in first-line therapy for breast cancer , 2006, Expert opinion on emerging drugs.

[19]  Peter A. Jones,et al.  Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. , 2006, Cancer cell.

[20]  Shingo Takagi,et al.  MicroRNA regulates the expression of human cytochrome P450 1B1. , 2006, Cancer research.

[21]  M. Gottesman,et al.  The molecular basis of multidrug resistance in cancer: The early years of P‐glycoprotein research , 2006, FEBS letters.

[22]  Martin A Nowak,et al.  Evolution of Resistance During Clonal Expansion , 2006, Genetics.

[23]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[24]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[25]  Mihaela Zavolan,et al.  Effects of Dicer and Argonaute down-regulation on mRNA levels in human HEK293 cells , 2006, Nucleic acids research.

[26]  R. Glasspool,et al.  Epigenetics as a mechanism driving polygenic clinical drug resistance , 2006, British Journal of Cancer.

[27]  E. Miska,et al.  miRNAs in cancer: approaches, aetiology, diagnostics and therapy. , 2007, Human molecular genetics.

[28]  R. Weinberg,et al.  Tumour invasion and metastasis initiated by microRNA-10b in breast cancer , 2007, Nature.

[29]  Simion I. Chiosea,et al.  Overexpression of Dicer in precursor lesions of lung adenocarcinoma. , 2007, Cancer research.

[30]  Gail Mandel,et al.  Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA , 2007, Nature Neuroscience.

[31]  P. Holm,et al.  Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes. , 2007, International journal of oncology.

[32]  T. Fojo.  Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[33]  Carlos Caldas,et al.  MicroRNA expression profiling of human breast cancer identifies new markers of tumour subtype , 2007 .

[34]  B. White,et al.  The Micro-Ribonucleic Acid (miRNA) miR-206 Targets the Human Estrogen Receptor-α (ERα) and Represses ERα Messenger RNA and Protein Expression in Breast Cancer Cell Lines , 2007 .

[35]  Leonard D. Goldstein,et al.  MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype , 2007, Genome Biology.

[36]  S. Spivack,et al.  Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. , 2007, Cancer research.

[37]  O. Kovalchuk,et al.  Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets , 2007, Molecular Cancer Therapeutics.

[38]  T. Golub,et al.  Impaired microRNA processing enhances cellular transformation and tumorigenesis , 2007, Nature Genetics.

[39]  R. Sachs,et al.  Cancer drug resistance: the central role of the karyotype. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[40]  K. Ghoshal,et al.  MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. , 2007, Gastroenterology.

[41]  Imran Babar,et al.  MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. , 2007, Cancer research.

[42]  Molly Megraw,et al.  miRGen: a database for the study of animal microRNA genomic organization and function , 2006, Nucleic Acids Res..

[43]  M. D'Esposito,et al.  Chromosome territory reorganization in a human disease with altered DNA methylation , 2007, Proceedings of the National Academy of Sciences.

[44]  James W Jacobson,et al.  MicroRNA: Potential for Cancer Detection, Diagnosis, and Prognosis. , 2007, Cancer research.

[45]  R. Stallings,et al.  MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells , 2007, Oncogene.

[46]  C. Morrison,et al.  MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B , 2007, Proceedings of the National Academy of Sciences.

[47]  J. Fridlyand,et al.  Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. , 2007, Cancer research.

[48]  Michael J Kerin,et al.  MicroRNAs as Prognostic Indicators and Therapeutic Targets: Potential Effect on Breast Cancer Management , 2008, Clinical Cancer Research.

[49]  Huan Yang,et al.  MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. , 2008, Cancer research.

[50]  Shuomin Zhu,et al.  MicroRNA-21 targets tumor suppressor genes in invasion and metastasis , 2008, Cell Research.